| Literature DB >> 27313831 |
Shreesh Ojha1, Hasan Al Taee1, Sameer Goyal2, Umesh B Mahajan2, Chandrgouda R Patil2, D S Arya3, Mohanraj Rajesh1.
Abstract
Doxorubicin (DOX) is a potent and widely used anthracycline antibiotic for the treatment of several malignancies. Unfortunately, the clinical utility of DOX is often restricted due to the elicitation of organ toxicity. Particularly, the increased risk for the development of dilated cardiomyopathy by DOX among the cancer survivors warrants major attention from the physicians as well as researchers to develop adjuvant agents to neutralize the noxious effects of DOX on the healthy myocardium. Despite these pitfalls, the use of traditional cytotoxic drugs continues to be the mainstay treatment for several types of cancer. Recently, phytochemicals have gained attention for their anticancer, chemopreventive, and cardioprotective activities. The ideal cardioprotective agents should not compromise the clinical efficacy of DOX and should be devoid of cumulative or irreversible toxicity on the naïve tissues. Furthermore, adjuvants possessing synergistic anticancer activity and quelling of chemoresistance would significantly enhance the clinical utility in combating DOX-induced cardiotoxicity. The present review renders an overview of cardioprotective effects of plant-derived small molecules and their purported mechanisms against DOX-induced cardiotoxicity. Phytochemicals serve as the reservoirs of pharmacophore which can be utilized as templates for developing safe and potential novel cardioprotective agents in combating DOX-induced cardiotoxicity.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27313831 PMCID: PMC4893565 DOI: 10.1155/2016/5724973
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1This scheme shows the pathways involved in the elicitation of DOX-induced adverse effects in the myocardium and its attenuation by phytochemicals.
Phytochemicals investigated for cardioprotective activity against DOX-induced cardiotoxicity in in vivo studies.
| Phytochemical | DOX-induced cardiomyopathy-animal model (acute or chronic) | Cardiac function determined (yes/no) | References |
|---|---|---|---|
| Arjunolic acid | Chronic | Yes | [ |
|
| |||
| Berberine | Chronic | Yes | [ |
|
| |||
| Berberine | Acute | Yes | [ |
|
| |||
| Baicalein | Chronic | No | [ |
|
| |||
| Caffeic acid phenethyl ester | Acute | Yes | [ |
|
| |||
| Cannabidiol | Acute | Yes | [ |
|
| |||
| Cannabidiol | Chronic | No | [ |
|
| |||
| Carotenoids | Acute | No | [ |
|
| |||
| Eugenol | Acute | Yes | [ |
|
| |||
| Gingerol | Chronic | No | [ |
|
| |||
| 23-Hydroxybetulinic acid | Chronic | Yes | [ |
|
| |||
| Hesperetin | Chronic | No | [ |
|
| |||
| Hesperidin | Acute | No | [ |
|
| |||
| Isorhamnetin | Chronic | No | [ |
|
| |||
| Indole-3-carbinol | Chronic | No | [ |
|
| |||
| Kaempferol | Chronic | No | [ |
|
| |||
| Lycopene | Acute | No | [ |
|
| |||
| Lycopene | Acute | No | [ |
|
| |||
| Lycopene | Acute | Yes | [ |
|
| |||
| Mangiferin | Acute | No | [ |
|
| |||
| Mangiferin | Acute | No | [ |
|
| |||
| Naringenin | Acute | No | [ |
|
| |||
| Naringenin | Acute | No | [ |
|
| |||
| Ocotillol | Acute | No | [ |
|
| |||
| Ocotillol | Chronic | No | [ |
|
| |||
| Hydroxytyrosol | Chronic | No | [ |
|
| |||
| Tetrandrine | Chronic | Yes | [ |
|
| |||
| Periplogenin | Chronic | No | [ |
|
| |||
| p-coumaric acid | Acute | No | [ |
|
| |||
| Procyanidins | Chronic | Yes | [ |
|
| |||
| Robinin | Acute | No | [ |
|
| |||
| Thymoquinone | Acute | No | [ |
|
| |||
| Thymoquinone | Acute | No | [ |
|
| |||
| Silibinin | Chronic | Yes | [ |
|
| |||
| Sesamin | Acute | No | [ |
|
| |||
| Sesamol | Chronic | No | [ |
|
| |||
| Tetrahydroxystilbene glucoside | Acute | No | [ |
|
| |||
| Oleuropein | Acute | No | [ |
|
| |||
| Oleuropein | Acute | No | [ |
|
| |||
| Oleuropein | Chronic | Yes | [ |
|
| |||
| Frederine | Acute | Yes | [ |
|
| |||
| Visnagin | Acute | Yes | [ |
|
| |||
| Visnagin | Chronic | Yes | [ |
|
| |||
| Schisandrin B | Acute | Yes | [ |
|
| |||
| Schisandrin B | Chronic | Yes | [ |
|
| |||
| Salvianolic acid A | Acute | Yes | [ |
|
| |||
| Tanshinone IIA | Chronic | Yes | [ |
|
| |||
| Oleuropein | Acute | No | [ |
|
| |||
| Oleuropein | Acute | No | [ |
|
| |||
| Oleuropein | Chronic | Yes | [ |
|
| |||
| Frederine | Acute | Yes | [ |
|
| |||
| Visnagin | Acute | Yes | [ |
|
| |||
| Visnagin | Chronic | Yes | [ |
|
| |||
| Schisandrin B | Acute | Yes | [ |
|
| |||
| Schisandrin B | Chronic | Yes | [ |
|
| |||
| Salvianolic acid A | Acute | Yes | [ |
|
| |||
| Tanshinone IIA | Chronic | Yes | [ |
Phytochemicals exhibiting cytoprotection in the in vitro models of DOX-induced cardiotoxicity.
| Phytochemical | Concentration of the phytochemical | Cell culture model | DOX dose and time of incubation | References |
|
| ||||
| Arjunolic acid | 100 | Neonatal rat cardiomyocytes | 1 | [ |
|
| ||||
| Apigenin | 25–100 | Rat heart cardiomyocytes | 100 | [ |
|
| ||||
| Avicularin | 10–80 | H9c2 cells | 20 | [ |
|
| ||||
| Berberine | 0.06, 0.25, 1.0, and 4.0 | Neonatal rat cardiomyocytes and MCF-7 cells | 1 | [ |
|
| ||||
| Baicalein | 25 | Chick embryo cardiomyocytes and MCF-7 cells | 1, 10, 50, or 100 | [ |
|
| ||||
| Calceolarioside | 40 | H9c2 cells | 1, 2, or 5 | [ |
|
| ||||
| 23-Hydroxybetulinic acid | 0.2, 2, and 20 | H9c2 cells | 5 | [ |
|
| ||||
| Isorhamnetin | 3.125 to 25 | MCF-7, HepG2, and Hep2 cells | 1 | [ |
|
| ||||
| Kaempferol | 5 to 50 | H9c2 cells | 1 | [ |
|
| ||||
| Morin hydrate | 0.17 mM | ECV304 and HepG2 cells | 6 mM for 12 h | [ |
|
| ||||
| Naringenin-7-O-glucoside | 10–80 | H9c2 cells | 10 | [ |
|
| ||||
| Osthole | 10–40 | Neonatal rat cardiomyocytes | 1 | [ |
|
| ||||
| Luteolin-7- | 5, 10, and 20 | H9c2 cells | 20 | [ |
|
| ||||
| Luteolin-7- | 5–80 | H9c2 cells | 10 | [ |
|
| ||||
| Vincristine | 10–30 | Adult mouse cardiomyocytes | 15 and 20 | [ |
|
| ||||
| Sulforaphane | 2.5 | H9c2 cells | 5 | [ |
|
| ||||
| C-Phycocyanin | 10 | Adult rat cardiomyocytes | 10 | [ |
|
| ||||
| Plantainoside D | 1–20 | H9c2 cells | 1, 2, and 4 | [ |
|
| ||||
| Sesamol | 12.5–50 | H9c2 cells | 1 | [ |
|
| ||||
| Tetrahydroxystilbene glucoside | 3–300 | Neonatal rat cardiomyocytes | 1 | [ |
|
| ||||
| Chrysoeriol | 20 | H9c2 cells | 1 | [ |
|
| ||||
| Visnagin | 20 | Neonatal rat and zebrafish cardiomyocytes, cardiac HL-1 cells | 100 | [ |
|
| ||||
| Z-Guggulsterone | 1–30 | H9C2 cells | 1 | [ |
|
| ||||
| Tanshinone IIA | 0.1, 0.3, 1, and 3 | Neonatal rat cardiomyocytes | 1 | [ |
|
| ||||
| Tanshinone IIA | 1.6–40 | H9c2 cells | 1 | [ |
|
| ||||
| Tanshinone IIA | 0.5, 1, and 2 | Neonatal rat cardiomyocytes | 1 | [ |
|
| ||||
| Sodium tanshinone IIA sulphonate | 0.05–0.5 mM | Mice heart mitochondria | 0.2 mmol for 10 min | [ |
|
| ||||
| Anthocyanidins and anthocyanins | 0–100 | H9c2 cells and MCF-7 cells | 1 | [ |
|
| ||||
| Caffeic, chlorogenic, and rosmarinic acid | 100 and 200 | Rat heart microsomes and mitochondria | 100 | [ |
ECV304 cells: human umbilical vein endothelial cells; HepG2 cells: human hepatocellular carcinoma cells; MCF-7 cells: human breast carcinoma; H9c2 cells: rat ventricular cardiomyoblast cells.